A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Summary

Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China

Timeline

Start

2020-07-23

Primary completion

2021-08-24

Completion

2021-08-24

Outcome

Met primary endpoint

release “Analysis of primary endpoint revealed both 340 and 680 mg of batoclimab treatment resulted in rapid, clinically meaningful, and statistically significant improvements over placebo” harbourbiomed.com ↗

Publications

• Yan C, Duan RS, Yang H, Li HF, Zou Z, Zhang H, Zhou H, Li XL, Zhou H, Jiao L, Chen J, Yin J, Du Q, Lee M, Chen Y, Chen X, Zhao C. Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study. Neurol Ther. 2022 Jun;11(2):815-834. doi: 10.1007/s40120-022-00345-9. Epub 2022 Apr 12.

Drugs

Indications